Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol
Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol
复制标题
DOI：
10.1161/strokeaha.119.028718
复制
发表时间：
2020-04-01
期刊：
影响因子：
8.3
通讯作者：
Bruckert, Eric
中科院分区：
文献类型：
--
作者：
Amarenco, Pierre;Kim, Jong S.;Bruckert, Eric
背景与目的——TST试验（靶向治疗卒中试验）评估了在法国和韩国人群中将低密度脂蛋白胆固醇目标设定为4 mmol/L的益处。法国患者的随访中位数为5.3年（与SPARCL试验［通过积极降低胆固醇水平预防卒中］的中位随访时间相似），韩国患者为2.0年。他汀类药物的暴露持续时间是降低心血管风险的一个众所周知的驱动因素。我们在此报告法国队列的TST结果。方法——1073名法国患者被分配至……
Background and Purpose-The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of 4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results in the French cohort.Methods-One thousand seventy-three French patients were assigned to